Now What? Sanofi CEO Urges Incentives As China Embraces New Drugs

Delinking drug approvals from price agreements, and providing timely and adequate reimbursement coverage, are just some of the policy changes top big pharma executives would like to see if China is to create an operating environment conducive to innovation.